These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17190842)

  • 21. Imatinib-induced pseudoporphyria.
    Timmer-de Mik L; Kardaun SH; Kramer MH; Hayes DP; Bousema MT
    Clin Exp Dermatol; 2009 Aug; 34(6):705-7. PubMed ID: 19077095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
    Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
    Brouard MC; Prins C; Mach-Pascual S; Saurat JH
    Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.
    Foringer JR; Verani RR; Tjia VM; Finkel KW; Samuels JA; Guntupalli JS
    Ann Pharmacother; 2005 Dec; 39(12):2136-8. PubMed ID: 16288076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
    Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
    Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript].
    Liu HX; Cao XY; Tong CR; Wu T; Wang T; Fan QZ; Wu P; Zhang X; Cai P; Zhu P
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):220-3. PubMed ID: 19552835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irreversible sensorineural hearing loss due to Imatinib.
    Attili VS; Bapsy PP; Anupama G; Lokanatha D
    Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical characterization of cutaneous drug eruptions by STI571.
    Park HJ; Kim HS; Kim HJ; Lee JY; Cho BK; Lee AW; Yoon DY; Cho DH
    J Dermatol Sci; 2005 Apr; 38(1):9-15. PubMed ID: 15795119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.
    Shenton JM; Teranishi M; Abu-Asab MS; Yager JA; Uetrecht JP
    Chem Res Toxicol; 2003 Sep; 16(9):1078-89. PubMed ID: 12971795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol.
    Hsieh HJ; Chan AL; Lin SJ
    Chemotherapy; 2009; 55(4):197-9. PubMed ID: 19439939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
    Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
    J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
    Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
    Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.